Stay updated with breaking news from Epigenetic Regulator Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
DURECT Co. (NASDAQ:DRRX – Get Rating) saw a significant decrease in short interest in April. As of April 15th, there was short interest totalling 339,900 shares, a decrease of 19.9% from the March 31st total of 424,200 shares. Based on an average daily volume of 94,600 shares, the days-to-cover ratio is currently 3.6 days. Approximately […]
Susquehanna International Group LLP acquired a new stake in shares of DURECT Co. (NASDAQ:DRRX – Get Rating) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 11,954 shares of the specialty pharmaceutical company’s stock, valued at approximately $41,000. Susquehanna International […]
DURECT Co. (NASDAQ:DRRX – Get Rating) was the target of a significant increase in short interest in March. As of March 31st, there was short interest totalling 424,200 shares, an increase of 13.6% from the March 15th total of 373,300 shares. Based on an average trading volume of 104,600 shares, the short-interest ratio is presently […]
Regis Management CO LLC cut its position in DURECT Co. (NASDAQ:DRRX – Get Rating) by 90.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 13,425 shares of the specialty pharmaceutical company’s stock after selling 120,825 shares during the quarter. Regis Management […]
Analysts expect that DURECT Co. (NASDAQ:DRRX – Get Rating) will post sales of $2.43 million for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for DURECT’s earnings, with estimates ranging from $2.00 million to $2.85 million. DURECT reported sales of $2.21 million during the same quarter last year, which would indicate […]